



with Extended Prophylaxis. *The American Journal of Medicine* [online]. 2018 [cit. 2019–02–25]. DOI: 10.1016/j.amjmed.2018.08.024. ISSN 00029343. Dostupné z: <https://linkinghub.elsevier.com/retrieve/pii/S0002934318308520>

9. Lekura J, Kalus JS. Overview of betrixaban and its role in clinical practice. *American Journal of Health-System Pharmacy*[online]. 2018, 75(15), 1095–1102 [cit. 2019–02–25]. DOI: 10.2146/ajhp170785. ISSN 1079-2082. Dostupné z: <https://academic.oup.com/ajhp/article/75/15/1095/5102024>

10. Beyer-Westendorf J, Verhamme P, Bauersachs R. Betrixaban for prevention of venous thromboembolism in acute medically ill patients. *European Heart Journal Supplements* [online]. 2018, 20(suppl E), E16–E22 [cit. 2019–02–25]. DOI: 10.1093/eurheartj/suy017. ISSN 1520–765X. Dostupné z: [https://academic.oup.com/eurheartjsupp/article/20/suppl\\_E/E16/4993363](https://academic.oup.com/eurheartjsupp/article/20/suppl_E/E16/4993363)

11. Iwatsuki Y, Sato T, Moritani Y, Shigenaga T, et al. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. *European Journal of Pharmacology*[online]. 2011, 673(1–3), 49–55 [cit. 2019–03–19]. DOI: 10.1016/j.ejphar.2011.10.009. ISSN 00142999. Dostupné z: <https://linkinghub.elsevier.com/retrieve/pii/S0014299911012398>

12. Kaku S, Suzuki M, Saitoh M, Funatsu T, et al. Darexaban: Anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa. *Thrombosis Research* [online]. 2013, 131(5), 450–456 [cit. 2019–03–19]. DOI: 10.1016/j.thromres.2013.03.016. ISSN 00493848. Dostupné z: <https://linkinghub.elsevier.com/retrieve/pii/S0049384813001035>

13. Kadokura T, Kashiwa M, Groenendaal D, Heeringa M, et al. Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects. *Biopharmaceutics & Drug Disposition* [online]. 2013, 34(8), 431–441 [cit. 2019–03–19]. DOI: 10.1002/bdd.1858. ISSN 01422782. Dostupné z: <http://doi.wiley.com/10.1002/bdd.1858>

14. Hashimoto T, Suzuki K, Kihara Y, et al. Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans. *Xenobiotica* [online]. 2012, 43(6), 534–547 [cit. 2019–03–19]. DOI: 10.3109/00498254.2012.738045. ISSN 0049-8254. Dostupné z: <http://www.tandfonline.com/doi/full/10.3109/00498254.2012.738045>

15. Kadokura T, Groenendaal D, Heeringa M, Mol R, et al. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin. *European Journal of Drug Metabolism and Pharmacokinetics* [online]. 2014, 39(1), 1–9 [cit. 2019–03–19]. DOI: 10.1007/s13318–013–0141–1. ISSN 0378-7966. Dostupné z: <http://link.springer.com/10.1007/s13318–013–0141–1>

16. Kadokura T, Taniuchi Y, Inoue H, Saito M, et al. Effect of food on the pharmacokinetics

of darexaban, an oral direct factor Xa inhibitor, in healthy Japanese subjects. *Int. Journal of Clinical Pharmacology and Therapeutics* [online]. 2013, 51(03), 200–206 [cit. 2019–03–19]. DOI: 10.5414/CP201804. ISSN 0946-1965. Dostupné z: [http://www.dustri.com/article\\_response\\_page.html?artId=10188&doi=10.5414/CP201804&L=0](http://www.dustri.com/article_response_page.html?artId=10188&doi=10.5414/CP201804&L=0)

17. Eriksson B I, Turpie AGG, Lassen MR, et al. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). *Journal of Thrombosis and Haemostasis* [online]. 2010, 8(4), 714–721 [cit. 2019–03–20]. DOI: 10.1111/j.1538–7836.2010.03748.x. ISSN 15387933. Dostupné z: <http://doi.wiley.com/10.1111/j.1538–7836.2010.03748.x>

18. Steg Ph.G, Mehta SR, Jukema JW, et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. *European Heart Journal* [online]. 2011, 32(20), 2541–2554 [cit. 2019–03–20]. DOI: 10.1093/eurheartj/ehr334. ISSN 0195–668X. Dostupné z: <https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehr334>

19. Sakon M, Nakamura M. Darexaban (YM150) prevents venous thromboembolism in Japanese patients undergoing major abdominal surgery: Phase III randomized, mechanical prophylaxis-controlled, open-label study. *Thrombosis Research* [online]. 2012, 130(3), e52–e59 [cit. 2019–03–20]. DOI: 10.1016/j.thromres.2012.06.009. ISSN 00493848. Dostupné z: <https://linkinghub.elsevier.com/retrieve/pii/S0049384812002800>

20. Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Rocha E, et al. New parenteral anticoagulants in development. *Therapeutic Advances in Cardiovascular Disease*[online]. 2011, 5(1), 33–59 [cit. 2019–03–25]. DOI: 10.1177/1753944710387808. ISSN 1753-9447. Dostupné z: <http://journals.sagepub.com/doi/10.1177/1753944710387808>

21. Hinder M, Frick A, Jordaan P, Hesse G, et al. Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. *Clinical Pharmacology & Therapeutics*[online]. 2006, 80(6), 691–702 [cit. 2019–03–25]. DOI: 10.1016/j.clpt.2006.09.002. ISSN 00099236. Dostupné z: <http://doi.wiley.com/10.1016/j.clpt.2006.09.002>

22. Cohen M, Bhatt DL, Alexander JH, et al. Randomized, Double-Blind, Dose-Ranging Study of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention. *Circulation* [online]. 2007, 115(20), 2642–2651 [cit. 2019–03–25]. DOI: 10.1161/CIRCULATIONAHA.106.653428. ISSN 0009-7322. Dostupné z: <https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.106.653428>

23. Sabatine MS, EM Antman, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. *The Lancet* [online]. 2009, 374(9692), 787–795 [cit. 2019–03–25]. DOI: 10.1016/S0140–6736(09)61454–9. ISSN 01406736. Dostupné z: [http://doi.wiley.com/10.1016/S0140–6736\(09\)61454–9](http://doi.wiley.com/10.1016/S0140–6736(09)61454–9)